A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer

被引：12
作者：
El Rassy, Elie [1 ]
Bakouny, Ziad [1 ]
Aoun, Fouad [2 ]
Haddad, Fadi G. [3 ]
Sleilaty, Ghassan [3 ]
Assi, Tarek [1 ]
Kattan, Joseph [1 ]
机构：
[1] St Joseph Univ, Hotel Dieu France Univ Hosp, Fac Med, Dept Med Oncol, Beirut, Lebanon
[2] St Joseph Univ, Hotel Dieu France Univ Hosp, Fac Med, Dept Urol, Beirut, Lebanon
[3] St Joseph Univ, Fac Med, Dept Biostat, Beirut, Lebanon
来源：
IMMUNOTHERAPY | 2018年 / 10卷 / 08期
关键词：
atezolizumab; PD-1; inhibitor; PDL-1; pembrolizumab; urothelial bladder cancer; TRANSITIONAL-CELL CARCINOMA; PHASE-III TRIAL; 2ND-LINE THERAPY; CHEMOTHERAPY; GEMCITABINE; REGIMEN; IMMUNOTHERAPY; UPDATE;
D O I：
10.2217/imt-2017-0190
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Aim: To determine which of the approved immune checkpoint inhibitors is the optimal treatment in metastatic urothelial bladder cancer. Methods & materials: Only the pivotal Phase III trials of secondline metastatic urothelial bladder cancer were included in this network meta-analysis. Results: This NMA included three pooled trials (NCT00315237, NCT02256436 and NCT02302807) of 1125 participants. Pem-brolizumab was the only treatment with positive effect on overall survival compared with the best supportive care. The treatment discontinuation rates due to adverse events of the pembrolizumab and atezolizumab did not differ from that of the best supportive care. C onclusion: Our results confirmed the superiority of pembrolizumab in the management of metastatic urothelial bladder cancer.
引用
收藏
页码：657 / 663
页数：7
相关论文
共 23 条
  • [1] Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]
    Albers, P.
    Park, S. -I.
    Niegisch, G.
    Fechner, G.
    Steiner, U.
    Lehmann, J.
    Heimbach, D.
    Heidenreich, A.
    Fimmers, R.
    Siener, R.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (02) : 288 - 294
  • [2] PDL-1/PD1 inhibitors: antibody or antinobody?
    Aoun, Fouad
    El Rassy, Elie
    Assi, Tarek
    Kattan, Joseph
    [J]. FUTURE ONCOLOGY, 2017, 13 (19) : 1669 - 1671
  • [3] Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment
    Aoun, Fouad
    El Rassy, Elie
    Assi, Tarek
    Albisinni, Simone
    Katan, Joseph
    [J]. IMMUNOTHERAPY, 2017, 9 (05) : 451 - 460
  • [4] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
    Babjuk, Marko
    Boehle, Andreas
    Burger, Maximilian
    Capoun, Otakar
    Cohen, Daniel
    Comperat, Eva M.
    Hernandez, Virginia
    Kaasinen, Eero
    Palou, Joan
    Roupret, Morgan
    van Rhijn, Bas W. G.
    Shariat, Shahrokh F.
    Soukup, Viktor
    Sylvester, Richard J.
    Zigeuner, Richard
    [J]. EUROPEAN UROLOGY, 2017, 71 (03) : 447 - 461
  • [5] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [6] Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
    Bellmunt, Joaquim
    Theodore, Christine
    Demkov, Tomasz
    Komyakov, Boris
    Sengelov, Lisa
    Daugaard, Gedske
    Caty, Armelle
    Carles, Joan
    Jagiello-Gruszfeld, Agnieszka
    Karyakin, Oleg
    Delgado, Francois-Michel
    Hurteloup, Patrick
    Morsli, Nassim
    Salhi, Yacine
    Culine, Stephane
    von der Maase, Hans
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4454 - 4461
  • [7] Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
    Carbognin, Luisa
    Pilotto, Sara
    Milella, Michele
    Vaccaro, Vanja
    Brunelli, Matteo
    Calio, Anna
    Cuppone, Federica
    Sperduti, Isabella
    Giannarelli, Diana
    Chilosi, Marco
    Bronte, Vincenzo
    Scarpa, Aldo
    Bria, Emilio
    Tortora, Giampaolo
    [J]. PLOS ONE, 2015, 10 (06):
  • [8] Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
    Chen, Daniel S.
    Irving, Bryan A.
    Hodi, F. Stephen
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6580 - 6587
  • [9] Systemic Immunotherapy for the Treatment of Brain Metastases
    Cohen, Justine V.
    Kluger, Harriet M.
    [J]. FRONTIERS IN ONCOLOGY, 2016, 6
  • [10] Advances in the meta-analysis of heterogeneous clinical trials I: The inverse variance heterogeneity model
    Doi, Suhail A. R.
    Barendregt, Jan J.
    Khan, Shahjahan
    Thalib, Lukman
    Williams, Gail M.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2015, 45 : 130 - 138
123